Sunmax Biotechnology Co., Ltd. (TPEX:4728)

Market Cap	21.24B
Revenue (ttm)	1.95B
Net Income (ttm)	698.88M
Shares Out	54.46M
EPS (ttm)	12.82
PE Ratio	30.42
Forward PE	n/a
Dividend	11.60 (2.97%)
Ex-Dividend Date	Aug 4, 2025

Volume	3,043
Average Volume	13,411
Open	394.00
Previous Close	389.50
Day's Range	390.00 - 394.00
52-Week Range	267.00 - 501.00
Beta	-0.01
RSI	41.28
Earnings Date	Nov 11, 2025

About Sunmax Biotechnology

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4728

Financial Performance

In 2024, Sunmax Biotechnology's revenue was 1.82 billion, an increase of 7.64% compared to the previous year's 1.69 billion. Earnings were 679.41 million, an increase of 8.58%.